Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

for walking Responders compared to Non-responders (p less than 0.001). In addition, the mean scores on all 12 questions in the MSWS-12 were better for the Responder group than the Non-responder group.

Subject Global Impression and Clinician Global Impression scales were used as secondary validators of clinical meaningfulness. Both measures also showed statistically significant improvement among Responders compared to Non-responders (p = 0.0010 and p less than 0.0001, respectively).

Statistically significant increases in leg strength, as measured by the Lower Extremity Manual Muscle Test (LEMMT), were seen in both the drug-treated Timed Walk Responders (p = 0.0002) and the drug-treated Non-responders (p = 0.046), compared to placebo-treated patients.

In an unplanned, direct comparison of Fampridine-SR vs. placebo-treated groups, the following measures were significantly improved in the Fampridine-SR-treated group: mean change in walking speed (p = 0.0004), mean change in the Lower Extremity Manual Muscle Test (p = 0.0029), and mean change in the Ashworth score for spasticity (p = 0.021).

Andrew Blight, Ph.D, Chief Scientific Officer of Acorda Therapeutics, commented, "Walking impairment is one of the most pervasive and serious disabilities afflicting people with MS, and there are no currently approved therapies that are indicated to improve walking in this population. Fampridine-SR, if approved, may offer a novel treatment for improving walking ability in people with MS, one that may be complementary to currently available therapies. In this study, we also saw improvements in measures of leg strength and spasticity compared to the placebo group. In particular, even the Fampridine-SR group that did not show a consistent walking improvement still showed a statistically significant improvement in leg strength compared to the placebo group. Further clinical studies would be required to determine whether such additional improvements may be cli
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014 Kiromic, LLC, a ... addition of Kent Hance , the former chancellor of ... Hance retired as chancellor in July 2014, after raising $1.2 ... announce that Kent Hance , the most successful chancellor ... Kiromic team not only as an investor, but also as ...
(Date:9/19/2014)... , September 19, 2014 ... Market by Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture ... Users (Hospitals), Advanced technologies - Global Forecast to ... is poised to reach $19,786.3 Million by 2019 ... of 6.8% from 2014 to 2019. ...
(Date:9/19/2014)... Sept. 19, 2014  4WEB Medical announces the formal ... and ankle osteotomy implants on the market today ... annual meeting in Chicago .  The ... a surgeon,s osteotomy needs with 74 size options included in ... offerings of only 15 to 18 implant sizes, which ...
Breaking Medicine Technology:Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 44WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Biosciences, will be presenting at the Deutsche Bank 36th Annual ... presentation takes place on Wednesday, May 4, 2011 at 10:40 ... will be webcast and may be accessed on the Company,s ...
... Inc. (Nasdaq: AMLN ) will be presenting at ... Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 ... and chief financial officer at Amylin Pharmaceuticals, will provide a ... through the "Investors" section of Amylin,s corporate website at ...
Cached Medicine Technology:
(Date:9/19/2014)... (PRWEB) September 19, 2014 “Copay coupons,” ... sales of brand drugs among patients with prescription drug ... according to a new report from the Department ... General (OIG). Federal anti-kickback laws prohibit suppliers from offering ... by the federal government. , The report highlights that ...
(Date:9/19/2014)... 2014 BearCom, a nationwide provider ... the key role played by instant, one-to-one and ... healthcare industry. , “In healthcare, speed of ... and in emergency situations, can save precious seconds ... death,” said Hugh Johnston, Product & Purchasing Manager ...
(Date:9/19/2014)... More than half of human cancers have ... yet how these signals are controlled during tumor ... PhD, MD, and Svetlana Fayngerts, PhD, both researchers ... at the Perelman School of Medicine, University of ... described oncogenic protein, promotes cancer by targeting these ...
(Date:9/19/2014)... 19, 2014 Visiting Nurse Association (VNA) ... health care, hospice and palliative care and community-based care, ... Opening Bell yesterday at the New York Stock Exchange. ... and social entrepreneur to care for immigrant families suffering ... always worked to meet the urgent healthcare needs of ...
(Date:9/19/2014)... U.S. military troops deployed to sunny climates may have ... new study. Many returning troops reported getting ... military personnel developed blisters on their skin or noticed ... their moles since being deployed overseas. All of ... the study authors noted. "The past decade of ...
Breaking Medicine News(10 mins):Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 2Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 3Health News:BearCom Releases Guidelines on Using Two-Way Radios to Improve Communications and Enhance Patient Service in Healthcare 4Health News:New cancer drug target involving lipid chemical messengers 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2
... endoscopy is a well accepted tool for evaluation of ... some limitations due to restricted recording time and reduced ... preparation (e.g., prokinetic drugs, laxatives and defoaming agents) have ... However, to date no standardized protocol has been recommended ...
... with pancreatico-biliary carcinoma has been reported as a definite ... This study, performed by a team led by Professor ... in a research article to be published on April ... , The study evaluated 31 patients who underwent paraaortic ...
... SAN ANTONIO, May 20 Medco Health Solutions,Inc. ... benefit manager, and,Healthways (Nasdaq: HWAY ), the ... announced the opening of an innovative new,center that ... managing health risks and chronic conditions. The Medco ...
... Recognized Nationally-, WASHINGTON, May 20 Michelle Mays, ... Advocate of the Year,by the Campaign for Tobacco-Free Kids ... being honored at a gala in the nation,s,capital on ... winner,three other regional winners and a group winner., ...
... in the Water Just Like ... BioLab ... marketing communications agency, Fletcher Martin (, http://www.fletchermartin.com ) launched an interactive ... http://www.biolabuv.com ). The,banner-ad game is designed to entice consumers to ...
... available in Spanish . , , A research team from ... on the psychological process that triggers the craving or intense desire ... the brain mechanisms that activate this state and how to control ... Department of Personality, Evaluation and Psychological Treatment of the ...
Cached Medicine News:Health News:How does sodium phosphate combined with bisacodyl affect small intestine? 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 2Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 3Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 4Health News:Medco, Healthways Launch Center for Health Action to Deliver Optimal Health(TM) 5Health News:Campaign for Tobacco-Free Kids Honors Michelle Mays of Rhinelander, WI As Youth Advocate of the Year 2Health News:Fletcher Martin Creates Interactive Game-Ad for BioLab(R) UV for BioGuard(R) 2Health News:A research on 'craving' for tobacco establishes the bases for addiction control 2
ROB-NEL Catheters (100% Latex-Free)...
Red Rubber Robinson Catheters (Latex)...
Urethral Red Rubber Catheters (Latex)...
Foley Catheters (Latex) 3-Way...
Medicine Products: